Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aradigm Corporation and APT Pharmaceuticals have moved an aerosolized formulation of an anti-inflammatory agent into phase II clinical trials. The partnership will test the drug in Aradigm's AERx pulmonary delivery system as a new class of treatment for asthma and chronic obstructive pulmonary disease.
Subscribe to our email newsletter
As part of the APT-funded program, Aradigm will source the active pharmaceutical ingredient, conduct the formulation development of the drug product, manufacture clinical supplies and execute regulatory and clinical development.
“This partnership combines an innovative formulation of a powerful anti-inflammatory agent with the efficient and precise delivery capabilities of the AERx System,” said Stephen Farr, chief scientific officer of Aradigm.
Aradigm and APT recently completed a phase I study in healthy volunteers, which determined that AERx delivered hydroxychloroquine (HCQ) had a favorable safety and tolerability profile that enabled progression into the phase II clinical program.
Recently, APT closed a round in a Series A financing with Charter Life Sciences and Research Corporation Technologies. The financing positions the company to continue its pulmonary product development program with Aradigm.